Ko-Ирбесан (Hydrochlorothiazide, Irbesartan)

Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. Irbesartan blocks AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone release. The combined effect reduces both vascular resistance and fluid overload, resulting in a greater overall drop in arterial pressure.

The appropriate dose of Ko-Ирбесан is determined by the prescribing healthcare professional based on the individual’s blood‑pressure goals, renal function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of the combination in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Ko-Ирбесан, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with monotherapy agents, the hydrochlorothiazide/irbesartan combination offers additive blood‑pressure reduction, often achieving target levels with a single pill. This can improve adherence versus taking two separate drugs. It is particularly useful when patients need both volume reduction and renin‑angiotensin system blockade.

Ko-Ирбесан tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Ko-Ирбесан is taken orally, usually once daily, with a full glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure consistent absorption.

Serious adverse events include severe dehydration, significant electrolyte disturbances (especially hyperkalemia or hyponatremia), angioedema, acute renal impairment, and life‑threatening hypotension. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight loss, dizziness, or marked changes in urine output.

Ko-Ирбесан is contraindicated in patients with known hypersensitivity to either component, severe renal or hepatic impairment, and in those who are pregnant unless the benefits outweigh the risks. It should also be avoided in individuals taking other potassium‑sparing agents without close monitoring.